Veterinary Therapeutics Based on Liposomes: Recent Advances

Authors

Keywords:

Liposome, laboratory animals, Pharmacological, drug bioavailability, veterinary industry

Abstract

In the veterinary industry, recent breakthroughs in nanomedicine have been investigated and have a wide range of uses. The use of liposomes to deliver medicinal compounds to animals has seen a significant increase in research interest over the last decade. Liposomes are nanosized phospholipid vesicles that can transport a range of substances. Liposomes are an easy-to-make, versatile, and effective delivery technology. They are harmless and biodegradable, with a lengthy in vivo circulation period. This review focuses on recent and ongoing veterinary medical research that may be of interest. This study portrays the current significance and prospects of liposome-based delivery in veterinary medicine by reviewing recent advancements in liposome-based treatments in animal malignancies, vaccinations, and analgesics.

References

Sadozai, H. and Saeidi, D., 2013. Recent developments in liposome-based veterinary therapeutics. International Scholarly Research Notices, 2013.

Brayden, D.J., Oudot, E.J. and Baird, A.W., 2010. Drug delivery systems in domestic animal species. Comparative and veterinary pharmacology, pp.79-112.

Underwood, C. and Van Eps, A.W., 2012. Nanomedicine and veterinary science: The reality and the practicality. The Veterinary Journal, 193(1), pp.12-23.

Irache, J.M., Esparza, I., Gamazo, C., Agüeros, M. and Espuelas, S., 2011. Nanomedicine: novel approaches in human and veterinary therapeutics. Veterinary parasitology, 180(1-2), pp.47-71.

Torchilin, V.P., 2005. Recent advances with liposomes as pharmaceutical carriers. Nature reviews Drug discovery, 4(2), pp.145-160.

Klibanov, A.L., Maruyama, K., Torchilin, V.P. and Huang, L., 1990. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS letters, 268(1), pp.235-237.

Blume, G. and Cevc, G., 1993. Molecular mechanism of the lipid vesicle longevity in vivo. Biochimica et Biophysica Acta (BBA)-Biomembranes, 1146(2), pp.157-168.

Gabizon, A.A., 2001. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer investigation, 19(4), pp.424-436.

Stealth® Liposomes, Chapter 19 (eds Martin, F. & Lasic, D.) 225–237 (CRC Press, Boca Raton, 1995).

Torchilin, V.P., Omelyanenko, V.G., Papisov, M.I., Bogdanov Jr, A.A., Trubetskoy, V.S., Herron, J.N. and Gentry, C.A., 1994. Poly (ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochimica et Biophysica Acta (BBA)-Biomembranes, 1195(1), pp.11-20.

Torchilin, V.P. and Trubetskoy, V.S., 1995. Which polymers can make nanoparticulate drug carriers long-circulating? Advanced drug delivery reviews, 16(2-3), pp.141-155.

Allen, T.M. and Hansen, C., 1991. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochimica et Biophysica Acta (BBA)-Biomembranes, 1068(2), pp.133-141.

Downloads

Published

2022-03-12

Issue

Vol. 10 No. 3 (2021)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.